FDA Approval during the Opioid Crisis: Sublingual Sufentanil

On November 2\textsuperscript{nd}, 2018, the FDA approved the use of 30 mcg sublingual sufentanil for use in certified healthcare facilities when alternative pain control is inadequate. The move has sparked debate in the healthcare industry over the appropriateness of approving a novel opioid at a time when abuse is widespread in many communities. The FDA defends their decision, pointing to the drug’s limited indications as a precaution against diversion. Sublingual sufentanil is marketed as Dsuvia in the U.S. and Zalviso in Europe.

- Sufentanil sublingual tablet 30mcg for moderate-to-severe acute pain in the ED. Miner JR, Rafique Z, Minkowitz HS, DiDonato KP, Palmer PP.

Bibliography by Rachel Becker, MLIS